Evaluation of the Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-related Pain With Inadequate Pain Relief or Intolerable Side Effects When Treated With Level 3 Opioids. (EQUIMETH2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01793480|
Recruitment Status : Unknown
Verified February 2013 by Laboratoires Bouchara-Recordati.
Recruitment status was: Recruiting
First Posted : February 15, 2013
Last Update Posted : February 18, 2013
This is a multicentric, randomized, open-label, phase IIIb national study, to evaluate the clinical effects (success/failure) of methadone for the treatment of cancer-related-pain in patients with inadequate pain relief or intolerable side effects when treated with level 3 opioid.
Principal objective is to compare the clinical effects (success/failure) of two methods of methadone titration in patients with cancer-related pain inadequately relieved or with intolerable side effects after treatment with level 3 opioid.
Secondary objectives are : Overall safety of methadone during the study, to describe the patients' characteristics, to describe the effects of methadone on pain relief, to describe the methadone administration, to evaluate patient's quality of life, to evaluate the prescriber's opinion regarding the handling of methadone initiation.
|Condition or disease||Intervention/treatment||Phase|
|Pain Related to Cancer||Drug: Methadone||Phase 3|
The randomisation (1:1) will consider the two titration methadone switching methods:
- Group A: patient-controlled dose of methadone with no overlapping with the previous opioid treatment
- Group B: fixed-dose of methadone with overlapping with the previous opioid treatment
Screening visit (Visit 1) within 48 hours before the inclusion Inclusion visit (Visit2) and randomisation on Day 1 Visit 3 from Day 2 to Day 7 (hospitalisation for all patients). Four follow-up visits on Day 14 (Visit 4), Day 21(Visit 5), Day 28 (Visit 6), Day 42 (Visit 7) End of study visit on Day 56 Follow-up phone contact on Day 84.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||146 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase IIIb Evaluation of the Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-related Pain With Inadequate Pain Relief or Intolerable Side Effects When Treated With Level 3 Opioids.|
|Study Start Date :||December 2011|
|Estimated Primary Completion Date :||September 2013|
Experimental: patient-controlled dose of methadone
The titration will be done on the patient's request (patient-controlled dose of methadone), with no overlapping with the previous opioid treatment, under the investigator's supervision.
Experimental: fixed-dose of methadone
The titration will be done with fixed-dose of methadone, on a progressive switch with overlapping with the previous opioid treatment, to avoid withdrawal syndrome when the opioid is discontinued.
- Binary main criterion based on success/failure rate related to methadone switch on Day 4. [ Time Frame: Day 4 ]
The success is defined as the adequate pain relief on Day 4 and no occurrence of overdose between Day 1 and Day 4. All unmet definition of success will be considered as a failure.
The adequate pain relief is defined as the composite criterion:
- Decrease of at least 2 points on the pain numeric scale from 0 (no pain) to 10 (unacceptable pain) evaluated on Day 4 when compared to the pain numeric scale score at baseline,
- And a pain numeric scale score <5 during two consecutive days (between Day 1 and Day 4)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01793480
|Contact: Shimsi Lefki, Drfirstname.lastname@example.org|
|Investigational Site 10||Recruiting|
|Investigational Site 06||Recruiting|
|Investigational Site 13||Recruiting|
|Investigational Site 03||Recruiting|
|Investigational Site 11||Recruiting|
|Le Chesnay, France|
|Investigational Site 07||Recruiting|
|Investigational Site 16||Recruiting|
|Investigational Site 12||Recruiting|
|Investigational Site 14||Active, not recruiting|
|Investigational Site 02||Recruiting|
|Pierre Benite, France|
|Investigational Site 05||Recruiting|
|Investigational site 08||Recruiting|
|Investigational Site 17||Recruiting|
|Investigational Site 01||Recruiting|
|Investigational Site 04||Active, not recruiting|
|Investigational Site 15||Recruiting|